LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Arcutis Biotherapeutics Inc

Fechado

SetorSaúde

14.06 3.15

Visão Geral

Variação de preço das ações

24h

Atual

Mín

13.6

Máximo

14.15

Indicadores-chave

By Trading Economics

Rendimento

-14M

-25M

Vendas

-5.5M

66M

EPS

-0.2

Margem de lucro

-38.059

Funcionários

342

EBITDA

-20M

-25M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+40.74% upside

Dividendos

By Dow Jones

Próximos Ganhos

13 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-101M

1.7B

Abertura anterior

10.91

Fecho anterior

14.06

Sentimento de Notícias

By Acuity

24%

76%

46 / 382 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

Arcutis Biotherapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

15 de mai. de 2025, 22:52 UTC

Ganhos
Grandes Movimentos do Mercado

Virgin Galactic Shares Rise on Commercial Spaceflight Plans, Narrower 1Q Loss

15 de mai. de 2025, 20:37 UTC

Principais Notícias
Ganhos

Applied Materials Logs Higher 2Q Profit, Revenue as Customer Demand Remains Unchanged

16 de mai. de 2025, 00:00 UTC

Conversa de Mercado

Xero Bull Stays Positive on Cost Outlook -- Market Talk

15 de mai. de 2025, 23:47 UTC

Conversa de Mercado

Gold Consolidates; Likely Supported by Signs of Disinflation -- Market Talk

15 de mai. de 2025, 23:38 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

15 de mai. de 2025, 23:38 UTC

Conversa de Mercado

Nikkei May Edge Higher, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

15 de mai. de 2025, 23:14 UTC

Principais Notícias

Walmart Becomes Biggest Retailer Yet to Pass Through Tariff Price Increases -- 4th Update

15 de mai. de 2025, 22:46 UTC

Principais Notícias
Aquisições, Fusões, Aquisições de Empresas

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 de mai. de 2025, 22:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

15 de mai. de 2025, 22:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

15 de mai. de 2025, 22:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 de mai. de 2025, 21:58 UTC

Ganhos

Applied Materials Earnings Beat Expectations. Why the Stock Is Down. -- Barrons.com

15 de mai. de 2025, 21:24 UTC

Ganhos

Cava's Earnings Beat Expectations. Growth Was Strong Despite Tariff Fears. -- Barrons.com

15 de mai. de 2025, 20:56 UTC

Conversa de Mercado

U.S. Spending Downturn Could Lie Ahead -- Market Talk

15 de mai. de 2025, 20:54 UTC

Conversa de Mercado
Ganhos

Applied Materials CFO Says Demand Stable Despite Tariffs, Macro -- Market Talk

15 de mai. de 2025, 20:54 UTC

Ganhos

Applied Materials Investing to Support Semiconductor Market of More Than $1T by End of Decade, Financial Chief Says

15 de mai. de 2025, 20:51 UTC

Ganhos

Applied Materials Financial Chief: Long-Term Secular Growth Drivers Remain Intact

15 de mai. de 2025, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

15 de mai. de 2025, 20:50 UTC

Aquisições, Fusões, Aquisições de Empresas

Berkshire Sells Financial Stocks, Doubles Constellation Stake, Holds Steady on Apple -- WSJ

15 de mai. de 2025, 20:50 UTC

Ganhos

Applied Materials' Customer Investments Continue at Expected Rate and Pace, Financial Chief Says

15 de mai. de 2025, 20:47 UTC

Ganhos

Applied Materials Not Currently Seeing Large Changes in Customer Demand, CEO Says

15 de mai. de 2025, 20:47 UTC

Ganhos

Applied Materials Sees Revenue From Advanced DRAM Customers to Grow 40% in FY25, CEO Says

15 de mai. de 2025, 20:47 UTC

Ganhos

Applied Materials Grew Faster Than Peers in Markets Outside China in 2Q, CEO Says

15 de mai. de 2025, 20:47 UTC

Ganhos

Applied Materials Underperformed Market in China in 2Q Due to Restrictions on U.S. Companies, CEO Says

15 de mai. de 2025, 20:37 UTC

Ganhos

SOS Ltd: Growth Was Fueled by Robust Domestic Demand and Expansion of Pdt Portfolio to Include Rubber and Coal >SOS

15 de mai. de 2025, 20:37 UTC

Ganhos

SOS Ltd: Cryptocurrency Mining Rev Declined to $9.3M From $18.9M in FY23, Dip Was Attributed to the Temporary Shutdown of Texas Mining Facility for Upgrades During 1H 2024 >SOS

15 de mai. de 2025, 20:37 UTC

Ganhos

SOS Ltd: FY24 Significant Yr-over-Yr Increase in Commodity Trading Rev, Which Soared to $214.3M FY24, 92.6% of Total Rev Up From 74.0% in FY23 >SOS

15 de mai. de 2025, 20:37 UTC

Ganhos

SOS Ltd: Cryptocurrency Mining Rev Halves as SOS Focuses on Facility Upgrades and Commodity Expansion >SOS

15 de mai. de 2025, 20:26 UTC

Principais Notícias

Trump Presses Apple to Bring iPhone Manufacturing to America. Wall Street Shrugs. -- WSJ

15 de mai. de 2025, 20:25 UTC

Ganhos

Deere Stock Jumps on Guidance Cut. Here's Why. -- Barrons.com

Comparação entre Pares

Variação de preço

Arcutis Biotherapeutics Inc Previsão

Preço-alvo

By TipRanks

40.74% parte superior

Previsão para 12 meses

Média 19.14 USD  40.74%

Máximo 21 USD

Mínimo 15 USD

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para Arcutis Biotherapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

8 ratings

7

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

12.42 / 14.93Suporte e Resistência

Curto Prazo

Strong Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bullish Evidence

Sentimento

By Acuity

46 / 382 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.